Bringing Bipolar I to Light: Connecting on Diagnosis & Treatment Challenges

Bipolar I disorder can be challenging to diagnose and treat. To address these challenges, three faculty experts came together during Mental Illness Awareness Week to discuss key issues in bipolar I disorder care. In this 60-minute activity previously aired as a live broadcast, the faculty discuss how you can overcome challenges in diagnosis and treatment adherence. Further, they utilize lecture, discussion, and debate to help you individualize treatment and discuss long-acting injectable (LAI) antipsychotics based on the evidence. 

Release date: October 10, 2020
Valid until: October 10, 2021

Review activity content under the Materials button (below).

Activity
Materials

Faculty

mcintyre
Roger S. McIntyre, MD, FRCPC

Professor of Psychiatry and Pharmacology, University of Toronto
Head, Mood Disorders Psychopharmacology Unit
Chairman and Executive Director, Brain and Cognition Discovery Foundation
Toronto, Ontario, Canada
Director, Depression and Bipolar Support Alliance
Chicago, Illinois
Professor and Nanshan Scholar, Guangzhou Medical University
Guangzhou, China
Adjunct Professor, Korea University College of Medicine
Seoul, Republic of Korea
Clinical Professor, SUNY Upstate Medical University
Syracuse, New York
Clinical Professor, Department of Psychiatry and Neurosciences
University of California, Riverside School of Medicine
Riverside, California 

bechersmith
Amy Becher-Smith, DNP, MSW, PMHNP, FNP 

Assistant Professor of Clinical Practice
The Ohio State University College of Nursing
Columbus, Ohio 

goldberg
Joseph F. Goldberg, MD, MS

Clinical Professor, Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New York 

Learning Objectives

As a result of participation in this educational activity, participants should increase their ability to:

Identify

Diagnose bipolar I disorder earlier in patients.

Recognize

Develop individual, evidence-based management plans for patients with bipolar I disorder.

reflect

Discuss LAI antipsychotics as a treatment option for appropriate patients with bipolar I disorder.

Initiate

Implement the latest strategies to improve patient adherence to bipolar I disorder treatment regimens.

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.  

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:  

  • Planners (Forefront Collaborative): Leah Johnson and Valerie Siclari, PhD 
  • Faculty Presenter: Amy Becher-Smith, DNP, MSW, PMHNP, FNP 
  • Faculty Planners: James Edgar Skye and Barbara Jones Warren, PhD, RN, APRN, PMHCNS-BC, FNAP, FAAN 

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:   

Faculty Presenter: Roger S. McIntyre, MD, FRCPC

  • Consultant: Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, and Takeda 
  • Speakers Bureau: Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, and Takeda 
  • Research or Grants From Private Industries or Nonprofit Funds: Stanley Medical Research Institute CIHR/GACD/National Natural Science Foundation of China 

Faculty Presenter: Joseph F. Goldberg MD, MS

  • Royalties: American Psychiatric Publishing and Cambridge University Press
  • Consultant: BioXcel, Otsuka, Neurocrine, Sage Pharmaceuticals, and Sunovion
  • Speakers Bureau: AbbVie, Intracellular Therapies, and Sunovion
  • Advisory Boards: Neurocrine, Otsuka, and Sunovion

Activity Information

Target Audience
This activity is designed for psychiatrists, psychiatric/mental health nurse practitioners (NPs) and physician assistants (PAs), and other healthcare professionals (HCPs) who treat patients with bipolar I disorder.

Accreditation Statement
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Content Review
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Otsuka America Pharmaceutical, Inc and Lundbeck.  

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose. 

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices. 

Provider
This activity is provided by Forefront Collaborative.

Commercial Support 
This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck. For further information concerning Otsuka and Lundbeck grant funding, visit www.OAPIgrants.com.

Open Registration